The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential.
Autologous stem cell transplantation (ASCT) is widely used to consolidate first remission in AML. We determined the significance of circulating CD34+ cells at the day of blood stem cell collection in 78 AML patients. Patients mobilizing more than 60,000 CD34+ cells/ml had shorter overall survival (OS; P=0.0274), shorter time to progression (TTP; P=0.0014), and a higher relapse rate (P=0.0177). High levels of CD34+ cells were an independent marker for shorter OS and TTP in a multivariate analysis. These data suggest that ASCT is associated with unfavorable outcome in AML patients with high levels of mobilized peripheral CD34+ cells.
Department of Medical Oncology, University Hospital and University of Berne, Berne, Switzerland.
Isabelle
I
von Grünigen
Joëlle
J
Raschle
Ilka
I
Rüsges-Wolter
Behrouz Mansouri
BM
Taleghani
Beatrice U
BU
Mueller
Thomas
T
Pabst
D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods* / Q000401:mortality*; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D014182:Transplantation, Autologous / Q000379:methods / Q000401:mortality; D055815:Young Adult
D018952:Antigens, CD34